
Preparing for the future
Hear the perspectives of multiple families about why it’s important to be knowledgeable about SMA and its management even after treatment.
Navigating life with SMA
Navigating life with SMA
SAMANTHA: When Stella was first diagnosed, I remember being so upset that there was a mom complaining that their child was pulling their hair. And here I am with my 3-week-old baby, who changed my world already, that wasn’t able to even move her arms to do so. She wasn’t able to grasp anything at that point. So I never ever forget when I felt a tug on my hair. And at first I thought, “Oh, I’m caught on something,” but when I looked down, Stella had her hand wrapped around my hair and that was something she had never done before.
JEREMY: It made me emotional because it’s one of the very first times that Samantha and I together saw Stella make a significant movement physically.
SAMANTHA: I went from not having those experiences to being very thankful for the littlest experiences that we were having. To watch her do the littlest things, they mean so, so much to us and has given us another perspective on everything in life.
Close the transcriptHear the perspectives of multiple families about why it’s important to be knowledgeable about SMA and its management even after treatment.
Hear an SMA family describe the moment their son walked into class on the first day of school and why it means so much to them.
Check out resources and advice from other caregivers to help you navigate your child’s future with SMA.
Get started
What is the most important information I should know about
ZOLGENSMA?
What is the most important information I should know about ZOLGENSMA?
What should I watch for before and after infusion with ZOLGENSMA?
What do I need to know about vaccinations and ZOLGENSMA?
Do I need to take precautions with the patient’s bodily waste?
What are the possible or likely side effects of ZOLGENSMA?
What is ZOLGENSMA?
ZOLGENSMA is a prescription gene therapy used to treat children less than 2 years old with spinal muscular atrophy (SMA). ZOLGENSMA is given as a one-time infusion into a vein. ZOLGENSMA was not evaluated in patients with advanced SMA.
The safety information provided here is not comprehensive. Talk to the patient’s doctor about any side effects that bother the patient or that don’t go away.
You are encouraged to report suspected side effects by contacting the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch, or Novartis Gene Therapies, Inc. at 833-828-3947.
Please see the Full Prescribing Information.